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Background: We aimed to determine the association of clinical and routine cerebrospinal fluid biochemical
markers (total protein, IgG index and oligoclonal bands) with disability in multiple sclerosis and whether these
biomarkers assessed at diagnosis add prognostic value.
Methods: We followed a cohort of patients included in the Multiple Sclerosis Lorraine Register (eastern France)
who had a diagnosis of multiple sclerosis for at least 5 years, as well as biological markers values and MRI findings
(Barkhof’s criteria). In a Cox regression model, endpoint was time to score of 4 on the Expanded Disability Status
Scale (EDSS) (i.e., limited time walking without aid or rest for more than 500 m).
Results: For 407 patients included, the median time from multiple sclerosis onset to EDSS score 4 was 4.5 years
[2.2–7.2]. Cerebrospinal fluid total protein factor < 500 mg/L was associated with EDSS score 4 on bivariate analysis
(hazard ratio 0.66, 95% confidence interval 0.46–0.95, p = 0.02). On multivariate analysis, older age at disease onset
(≥50 years) and initial primary progressive course of MS but not biological markers predicted worse prognosis.
Conclusion: Routine cerebrospinal fluid biological markers at diagnosis were not prognostic factors of multiple
sclerosis progression.
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Analysis of cerebrospinal fluid (CSF) has gained renewed
interest in diagnosis of multiple sclerosis (MS) [1,2], but
any prognostic value for disease progression is debated.
Among CSF markers, oligoclonal IgG bands (OCGBs)
are present in more than 95% of patients with MS [3,4]
and may have utility and prognostic value for MS diag-
nosis [5]. Another prognostic CSF marker may be IgG
index [6]. Some studies [7,8] have indicated a correlation
between index of IgG synthesis or number of OCGBs in
CSF and progression rate, but others have not [5,9-12].
Low number or absence of OCGBs in CSF at diagnosis
may predict better prognosis, particularly in terms of* Correspondence: francis.guillemin@chu-nancy.fr
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unless otherwise stated.disability [5,9,10,13-20]. However, the prognostic value
has not been established [21].
Among the various prognostic factors of disability in
MS, both primary progressive (PP) and remittent relap-
sing (RR) MS, the number of relapses in the first years
and MRI-determined lesional changes seemed to be the
most reliable [22-27]. However, most authors agree that
the clinical course cannot be predicted by initial symp-
toms alone [22]. A short interval between the 2 first
relapses [26], a rapid early course [27], a primary pro-
gressive course without remission [25-27] or onset at
older age [26-28] have all been associated with worse
long-term prognosis [29]. Sex may influence disease pro-
gression (female [23,25]; male [27]). CSF markers with
prognostic value at diagnosis would provide the phy-
sician with useful information early in the disease course
to adjust treatment, without waiting for further clinical
manifestations.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart of patient selection according to inclusion criteria.
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at MS diagnosis the role of routine CSF biochemical
variables, particularly IgG index and presence of OCGBs,
on disability (i.e., whether these biomarkers assessed at
diagnosis have prognostic value).
Methods
Source of the population
Patients were identified in the register of MS patients in
the Lorraine region of France. The main purpose of this
register is to record all incident cases of MS in Lorraine
[23,30] and follow them over time according to neurolo-
gists’ routine practice [31,32]. On November 1, 2011,
4,717 patients were registered.
Patient sampling
Inclusion criteria were time from MS onset (first signs
or symptoms) of at least 5 years [24], a lumbar puncture
within 10 years after the MS onset, with complete rou-
tine CSF biological data available (CSF OCGBs are stable
over time [33-35] thus reflecting status at diagnosis if
puncture was performed later), and Barkhof ’s criteria
available. Only patients with total protein, IgG index and
oligoclonal bands available were included in the study.
The clinically isolated syndrome (CIS) and radiologically
isolated syndrome (RIS) patients were excluded. From
the 4,717 patients potentially eligible for the study,
407 patients fulfilled the inclusion criteria (1997-2006)
(Figure 1).
The collection of register data was approved by the
French Advisory Committee on the Information pro-
cessing Research in the Field of Health (CCTIRS; refe-
rence N°10.258) in May 2010, and the French National
Commission for Data Protection and Liberties (CNIL;
reference N° 909089) in June 2006. Confidentiality and
safety of the data were ensured in accordance with these
recommendations. An informed consent for use of pa-
tient data was obtained from each participant.
Data collection
For the register, the neurologists collect data at diagnosis
and at each following routine consultation. When pa-
tients were notified to the register, all information since
MS onset was collected retrospectively, and patients
were entered in a prospective follow-up.
Data consistency is checked by use of the European
Database for MS (EDMUS) software with automatic
controls to reduce the frequency of incomplete or incor-
rect data [36].
For this study, we used demographic data; key epi-
sodes in the course of MS, including date of MS onset,
date of first and second episodes, and status of reco-
very from the first episode at the first relapse; Expanded
Disability Status Scale (EDSS) score, used to assess MSdisability [37], at each visit; and time of assignment of the
irreversible disability score, EDSS score 4 (EDSS 4; i.e.,
limited walking without aid or rest for more than 500 m).
MRI findings interpreted by initial Barkhof ’s criteria which
are: at least one Gadolinium-enhancing lesion or ≥9 T2
lesions, one Juxtacortical lesion, one Infratentorial lesion
and three Periventricular lesions; [38] were recorded. As
most patients had MRI performed at Nancy University
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criteria.
Recovery from the first relapse was classified as in-
complete (persistence of neurological signs, correspon-
ding to an EDSS score of at least 2) or complete
(absence of neurological signs, an EDSS score of 0 or 1).
The onset date of the second neurological episode of
MS, which may be a relapse or the onset of the progres-
sive phase, was systematically determined whenever
appropriate.
Biological samples and biochemical analyses
All analyses were performed at the biochemistry labora-
tory of the University Hospital of Nancy or at the biol-
ogy laboratory of the Regional Hospital of Thionville.
Matched CSF and serum were collected in the clinical
setting. All samples were immediately transported at
room temperature to the lab. Determination of leuko-
cytes count in CSF was assessed using a Nageotte hema-
tocytometer and microscopic observation. The presence
of more than 5 cells per mm3 was considered abnormal.
Then, CSF were quickly centrifuged at 2,000 × g for
10 min at 4°C and stored at -20°C. The level of CSF total
protein was measured by turbidimetry in both laborator-
ies. Concentrations of albumin and IgG were determined
in CSF and in serum by automated turbidimetry or
nephelemetry, respectively. These parameters were used
to calculate IgG index as (CSF IgG/serum IgG) × (serum
albumin/CSF albumin). A comparative analysis showed
no significant variation of the IgG index between both
methods. The threshold value for IgG index was set at
0.60 (personal unpublished data).
The presence of OCGBs in unconcentrated CSF was
determined by isoelectric focusing (IEF) followed by
immunoblotting [3]. Sensitivity for detecting OCGBs in
CSF using this “gold standard” method is higher than
95%, whatever the commercially available IEF apparatus
used [1]. A positive control was systematically used in
each gel run to determine the reliability of any given
run. Cut-off for OCGBs positivity was defined as 2 CSF-
restricted IgG bands. Because the presence of OCGBs in
CSF remains constant over the course of the disease,
results obtained within 10 years after MS onset, where
this technique was used, was considered present at diag-
nosis [33-35].
Statistical analysis
Quantitative data are expressed as mean ± SD, median
and range, quartiles and extreme values and qualitative
data by numbers and percentages. The normality of
variables was tested by the Kolmogorov-Smirnov test,
skewness and kurtosis. Comparison of 2 groups used chi-
square test for categorical variables and Student t test for
continuous variables. The time from disease onset toassignment of the irreversible score EDSS 4 was consi-
dered the endpoint. Subjects without this score and those
who died before the first occurrence of an irreversible
EDSS score were censored at the last follow-up. The time
to the endpoint was described by Kaplan-Meier estimates.
Bivariate analyses involved the log-rank test.
The Cox proportional-hazards regression model was
used to assess the predictive value of presence of OCGBs
and elevated IgG index on disability progression by
multivariate analysis, with adjustment for potential con-
founding variables: age at disease onset, gender, initial
form of MS, incomplete recovery at first relapse, protein
level, leukocyte count, IgG index, OCGBs, MRI lesions
(Barkhof ’s criteria), and time from MS onset.
Also, we defined a treatment variable, with treatment
(both immunomodulatory or immunosuppressive thera-
pies be it orally or intravenously administered) as present
as soon as the first treatment longer than six months be-
fore the time to assignment of irreversible EDSS4 for each
patient. We considered that this six months time thresh-
old was the minimal time after which we could estimate
the beneficial role of the treatment. We introduced the
treatment variable in the multivariate analysis.
Stepwise selection of variables was used with p = 0.20
for entering the model and p = 0.10 for staying in the
model. We tested the proportionality assumption and
the log linearity hypothesis. Because the proportional-
hazards assumption was not verified for some covariates,
we used a time-varying variable-extended Cox model [39].
Hazard ratios (HRs) and their 95% confidence intervals
(95% CIs) for disability progression (time to EDSS 4) were
calculated for parameters and were considered significant
at p < 0.05.
Statistical analysis involved SAS v9.3 for Windows
(SAS Inst., Cary, NC, USA).
Results
Baseline characteristics are in Table 1. The mean age at
MS onset was 33.0 ± 11.1 years. The median time bet-
ween MS onset and CSF testing was 4.6 years [1.0–7.0].
Among registered patients, those included and not in-
cluded in the study did not differ in age at onset (p = 0.41)
and gender (p = 0.31) but did differ in the initial form of
MS (p = 0.01) and incomplete recovery at first relapse
(p = 0.02).
During the initial course of MS, 349 patients had RR
disease at disease onset and 58 PP disease (Table 1). In
all, 142 patients had reached EDSS 4. The median time
from MS onset to assignment of irreversible EDSS4 by
the Kaplan-Meier method was 4.5 years [2.2–7.2]. In
total, 188 (46.2%) had elevated CSF IgG index and 354
(87%) CSF OCGBs. The mean IgG index was 0.6 ± 0.7
and mean CSF total protein level 345.5 ± 219.7 mg/L.
The proportion of CSF OCGBs was the same whatever
Table 1 General characteristics of 407 patients with
multiple sclerosis (MS)
N % Mean ± SD









Incomplete recovery from first relapse
No 346 85.0
Yes 61 15.0
Initial course of MS
Remitting-relapsing 349 85.7
Primary progressive 58 14.3











Increased (≥5 mm3) 256 62.9
Barkhof’s criteria (initial MRI)
Negative 48 11.8
Positive 359 88.2
Period of MS onset
<01/01/98 60 14.7
≥01/01/98 347 85.3
Time from MS onset to: (years)
Lumbar puncture 407 4.3 ± 3.2
Last follow-up 407 8.9 ± 3.8
EDSS: Expanded Disability Status Scale; CSF: cerebrospinal fluid; MRI: magnetic
resonance imaging.
Table 2 Association of patient characteristics and median
time from MS onset to expanded disability status scale
score 4
Characteristics N Events Median time to
EDSS4 (year)
p value
Age at onset of MS
<20 59 10 0.0001
20–28 110 28 19.1
29–38 119 48 10.0
39–49 87 32 12.2
≥50 32 24 4.2
Sex
Male 119 60 8.0 0.0001
Female 288 82 16.6
Initial course of MS
Remitting-relapsing 349 92 16.6 0.0001
Primary progressive 58 50 3.8
Incomplete recovery
from first relapse
No 346 117 19.1 0.3
Yes 61 25 11.9
CSF total protein level, mg/L
0–500 312 100 19.1 0.02
≥500 95 42 10.6
CSF IgG index
<0.60 219 83 16.6 0.6
≥0.60 188 59 11.4
CSF oligoclonal bands
Yes 354 119 16.6 0.7
No 53 23 12.2
Leukocyte count
Normal 151 57 11.9 0.2
Increased (≥5 mm3) 256 85 16.6
Barkhof’s criteria
(initial MRI)
Positive 359 129 16.6 0.4
Negative 48 13
Treatment
Yes 303 228 16.6 0.0001
No 104 37 4.9
P value: Kaplan-Meier method and Log-Rank Test; EDSS: Expanded Disability
Status Scale; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging.
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positives in RR and PP patients, respectively.
Table 2 gives the results of bivariate analyses of
variables associated with median time from MS onset to
EDSS4. Among biological variables, CSF total protein
level < 500 mg/L was associated with EDSS 4 (HR 0.66,95% CI 0.46–0.95). Older age at MS onset (≥29 years)
was associated with poor prognosis; for age between 29
and 38 years, the HR was 2.56 (95% CI 1.29–5.07) and
between 39 and 49 years, 2.58 (1.27–5.25). Univariate
analysis showed no significant association of Barkhof cri-
teria (HR 0.8, 95% CI 0.48–1.4; p = 0.4). Other variables
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(HR 0.15, 95% CI 0.10–0.21), female sex (HR 0.45, 95%
CI 0.32–0.62) and undergoing a treatment (HR 0.20,
95% CI 0.14–0.28).
The time to assignment of irreversible EDSS 4 did not
differ for patients without and with OCGBs (5.4 vs.
4.9 years, p = 0.52) and for patients with and without
IgG index < 0.60 (4.9 vs. 5.2 years, p = 0.65). This did not
differ when varying the IgG index threshold to < 0,65
(p = 0,73) or to < 0,7 (p = 0,81).
Table 3 presents the results of multivariate analysis
with extended Cox regression models and reveals no
significant impact of routine CSF biological markers on
assignment of EDSS 4. Even when adjusting for major
covariates at onset (age) and at diagnosis (sex, initial
course of MS, Barkhof ’s criteria, treatment), older age at
onset (≥50) (HR 2.48, 95% CI 1.11–5.55) and initial PP
course (HR 3.12, 95% CI 2.03–4.79) were associated with
poor prognosis, while OCGBs (HR 0.76, 95% CI 0.45–1.30)
and IgG index (HR 1.36, 95% CI 0.92–2.02) were not.
Discussion
We could not demonstrate any value of CSF IgG index
and presence of OCGBs at a mean of 8.9 ± 3.8 years of
follow-up for prognosis of disability in MS, which con-
trasts with previous studies [5-12,18] but is in line with
a recent study [40]. Older age at disease onset (≥50 years)
and initial PP course of MS were predictors of worsening
disability. In contrast with other studies [23,25,27,41,42],
gender was not a prognostic factor.
In recent years, several studies have suggested the prog-
nostic value of OCGBs in MS, showing good correlation
between disability and presence of OCGBs [9,10,16,43], asTable 3 Prognostic factors at diagnosis associated with EDSS
Characteristics




Sex (ref men) Women
Initial course of MS (ref primary progressive) Remitting-re
Incomplete recovery from the first relapse (ref yes) No
CSF total protein level (ref≥ 500) ≤500 mg/L
CSF IgG-index (ref ≥ 0.6) <0.6
CSF oligoclonal bands (ref yes) No
Leukocyte count (ref normal) ≥5 mm3
MRI Barkhof’s criteria (ref positive) Negative
Treatment (ref no) Yes
Multivariate analysis*: Extended Cox model; HR: hazard ratio; 95% CI: 95% confiden
magnetic resonance imaging.well as IgG index [44]. CSF OCGBs are stable over time
[33-35], which allowed us to consider it for subjects with
late lumbar puncture, as a reflection of the value of this
factor at diagnosis. However, whether CSF total protein
level and IgG index at the time of lumbar puncture
actually reflects their values at diagnosis is uncertain.
Many studies have investigated the prognosis of MS in
terms of biological markers [21,40,45]. Most studies have
focused on the RR form of MS. The absence of OCGBs
and low baseline T2-weighted lesions found on MRI
were favourable prognostic factors influencing the cli-
nical response to interferon β treatment in patients with
RR MS [16]. Age at disease onset and number of MS
attacks during the first 2 years of MS were predictors of
the evolution of the disability [46]. Blood levels of gene
markers [47], CSF IgM oligoclonal bands [48], the asso-
ciation of intrathecal Ig synthesis and cortical lesions
[49], simple detection of intrathecal IgG synthesis [9,44]
and initial relapse of RR MS have been studied as prog-
nosis markers of RR MS. Other studies have focused on
imaging and motor-evoked potentials [50] or the se-
condary progressive phase of MS [42].
Another recent study found that the presence of
OCGBs and elevated total CSF IgG and protein levels
moderately were associated with PP MS but not disease
progression [40]. As in our study, for patients who had
undergone multiple lumbar punctures, only the earliest
puncture was considered, and we found the same per-
centages for the RR form (85.7%) and PP form (14.3%).
However, the study differed from ours in a higher num-
ber of subjects, different biological technique for CSF
analysis, smaller time from MS onset to lumbar punc-
ture and no multivariate analysis.score 4 (n = 407)
Multivariate analysis*
HR 95% CI P value
1.25 0.60; 2.57 0.3
1.51 0.74; 3.06 0.08
1.43 0.68; 2.98 0.1
2.48 1.11; 5.55 0.01
1.42 0.99; 2.05 0.1
lapsing 0.20 0.13; 0.31 0.0001
1.10 0.69; 1.75 0.9
0.73 0.49; 1.08 0.4
1.36 0.92; 2.02 0.2
0.76 0.45; 1.30 0.6
1.08 0.74; 1.56 0.9
1.11 0.25; 4.91 0.9
0.29 0.20; 0.42 <.0001
ce interval; EDSS: Expanded Disability Status Scale; CSF: cerebrospinal fluid; MRI:
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sence of lesions as determined by T2-weighted baseline
magnetic resonance imaging (MRI) of the brain or
medullar tract increases chances of developing multiple
sclerosis. The degree of long-term disability from mul-
tiple sclerosis correlates with the volume increase of the
lesions seen on the brain MRI in the first five years only
[11,24] In our study, the change in volume over time
was not taken into account. Therefore, the absence of a
prognostic role of baseline MRI considering only the
Barkhof-Tintore criteria is not surprising.
For an early prognostic perspective, we entered only
covariates assessed at the time of MS onset in the
regression model. Compared with the other studies, we
were interested in the well-known prognostic markers
and new data at MS onset.
End of the 90’s was a milestone in the support of MS.
As noted earlier, the biological techniques to detect
OCGBs have evolved over time, especially after the
1990s, which must be considered in interpreting results.
In recent years, the isoelectric focusing technique of
CSF with IgG immunoassays was allowed for detecting
chronic inflammatory CSF, especially MS. Here, percent-
age of OCB negative patients is higher (12.9% for RR
and 13.8 for PP) than in previous works [10,51] where
percentage oscillated between 3-5%, with maximum
10.6% in Siritho’s work in 2009. It was reported a ten-
dency for lower prevalences in CSF from MS patients in
countries in southern of Europe compared to MS pa-
tients in northern countries. Although not available in
our study, information about the origin of our patients
might contribute to explain this atypical result [3,13,52].
Finally, the first eligible criterion, minimal time from
disease onset for at least 5 years, considerably decreased
the number of patients with CSF test results, because in
recent years, the database has had more complete data
from CSF tests.
The strengths of our study are that first, we conducted
multivariate analysis unlike most studies evaluating the
predictive value of routine CSF biological data which
used only bivariate analysis [4,12,17,43,49] and included
a low number of patients (<100) [9,10,43,47], except for
two studies [19,40]. Furthermore, only 2 studies claimed
they used adjustment for variables [10,16]. Yet, with our
relatively large sample size (n = 407), our results did not
show the predictive value of these biological markers.
Such differences might explain the previous contradic-
tory results. Second, patients were followed for a median
of 8.7 years (6.2–11.0), a long period as compared with
other studies [10,46,49,50].
Our study contains some limitations. The main diffi-
culty was the number of missing data relating to CSF,
which has several explanations. First, some neurologists
believe that CSF data are not important in the diagnosisof MS, particularly if the clinical and radiological criteria
leave no doubt. On another hand, for some patients
living far from major care center, it was not always
possible to perform lumbar puncture. Second, the infor-
mation might be available but not yet complete for some
patients, which led to our excluding data for some pa-
tients. Therefore, our cohort of 407 patients could have
been even larger, with higher statistical power. Third, we
had an exhaustive database, the Lorraine MS register,
with data for about 4,700 patients. From the overall
register population, patients who did and did not meet
the eligibility criteria were comparable in demographic
characteristics. Regarding the quality of the data, patient
records in the register are regularly updated when pa-
tients see their neurologist. However, although they were
identified in the register, patients retained in the sample
were likely more severe since more frequently diagnosed
at hospital center, as our team reported in a previous
paper [53]. But as a reflection of the recruitment from
the register, there was more heterogeneity in clinical
profile, in routine biological markers and in treatments.
Conclusions
In conclusion, our study, involving a large cohort of pa-
tients and multivariate analysis, could not demonstrate
the value of routine CSF biological markers at MS
diagnosis for prognosis of disability progression.
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